Read time: 3 minutes.  

One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment.  

Read time: 2 minutes.  

Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.  

On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung cancer (SCLC). 

This targeted immunotherapy, the first of its kind, is based on new technology. Tarlatamab is a bispecific T-cell engager (BiTE)—a drug with two arms that simultaneously binds to a T cell (a part of the immune system) and a tumor cell. This allows the T cell to come close enough to the tumor cell to recognize and destroy it. 

Read time: 2 minutes

Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. 

LUNGevity spoke to an expert to help sort out the facts from the fiction. 

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr.

This March, LUNGevity Foundation partnered with CURE for their ”Speaking Out” video series, featuring Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation. This interview with Dr. Moore delves into recent breakthroughs in the treatment of small cell lung cancer (SCLC). Dr.

Join small cell lung cancer expert Lauren Byers, MD, as she covers the key things patients need to know about SCLC in 30 minutes.  

Dr. Byers is a professor in the Department of Thoracic-Head & Neck Medical Oncology at MD Anderson Cancer Center. She is also a physician-scientist and a member of LUNGevity’s Scientific Advisory Board. 

The following topics are discussed at the times indicated:

0:00 – 5:03 Introduction and explanation of what small cell lung cancer (SCLC) is

5:03 – 8:49 Key features and common symptoms 

In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient.  

These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements.  

Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic questions to ask and get answered before making a decision are:

The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments.

Phases of a Clinical Trial:

1. Safety of the new treatment 
2. Does the cancer respond to the treatment 
3. Is this new treatment better than the current options 
4. Studies the long-term benefits and side effects